<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00688194</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000596572</org_study_id>
    <secondary_id>GIM-GIM8-OVER</secondary_id>
    <secondary_id>EUDRACT-2007-006031-30</secondary_id>
    <secondary_id>EU-20853</secondary_id>
    <secondary_id>GSK-GIM-GIM8-OVER</secondary_id>
    <secondary_id>ZENECA-GIM-GIM8-OVER</secondary_id>
    <nct_id>NCT00688194</nct_id>
  </id_info>
  <brief_title>Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy</brief_title>
  <official_title>Overcoming Endocrine Resistance in Metastatic Breast Cancer: A Randomized Trial With Factorial Design Comparing Fulvestrant ± Lapatinib ± Aromatase Inhibitor in Metastatic Breast Cancer Progressing After Aromatase Inhibitor Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Mammella (GIM)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using&#xD;
      fulvestrant and exemestane, anastrozole, or letrozole may fight breast cancer by blocking the&#xD;
      use of estrogen by the tumor cells and by lowering the amount of estrogen the body makes.&#xD;
      Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell&#xD;
      growth. It is not yet known whether fulvestrant is more effective with or without lapatinib&#xD;
      and/or aromatase inhibitor therapy in treating breast cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying fulvestrant with or without lapatinib&#xD;
      and/or aromatase inhibitor therapy to compare how well they work in treating postmenopausal&#xD;
      women with metastatic breast cancer that progressed after previous aromatase inhibitor&#xD;
      therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To compare the progression-free survival of postmenopausal women with progressive&#xD;
           metastatic breast cancer treated with fulvestrant with or without lapatinib tosylate&#xD;
           and/or aromatase inhibitor therapy.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To compare time to progression in these patients.&#xD;
&#xD;
        -  To compare overall survival of these patients.&#xD;
&#xD;
        -  To compare response rates in these patients.&#xD;
&#xD;
        -  To compare clinical benefit rates in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to timing of&#xD;
      progressive disease (during adjuvant therapy vs &gt; 12 months after completion of adjuvant&#xD;
      therapy vs during treatment for metastatic disease). Patients are randomized to 1 of 4&#xD;
      treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive fulvestrant intramuscularly (IM) on days 0, 14, and 28 of course&#xD;
           1 and on day 1 of all subsequent courses. Patients also receive oral placebo once daily&#xD;
           on days 1-28. Courses repeat every 28 days in the absence of disease progression or&#xD;
           unacceptable toxicity.&#xD;
&#xD;
        -  Arm II: Patients receive fulvestrant and placebo as in arm I. Patients also receive&#xD;
           aromatase inhibitor (AI) therapy (e.g., exemestane, anastrozole, or letrozole) according&#xD;
           to standard treatment regulations.&#xD;
&#xD;
        -  Arm III: Patients receive fulvestrant as in arm I and oral lapatinib tosylate once daily&#xD;
           on days 1-28. Courses repeat every 28 days in the absence of disease progression or&#xD;
           unacceptable toxicity.&#xD;
&#xD;
        -  Arm IV: Patients receive fulvestrant as in arm I and lapatinib as in arm III. Patients&#xD;
           also receive AI therapy according to standard treatment regulations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2008</start_date>
  <primary_completion_date type="Anticipated">May 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate</measure>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">396</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive fulvestrant intramuscularly (IM) on days 0, 14, and 28 of course 1 and on day 1 of all subsequent courses. Patients also receive oral placebo once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive fulvestrant and placebo as in arm I. Patients also receive aromatase inhibitor (AI) therapy (e.g., exemestane, anastrozole, or letrozole) according to standard treatment regulations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive fulvestrant as in arm I and oral lapatinib tosylate once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm IV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive fulvestrant as in arm I and lapatinib as in arm III. Patients also receive AI therapy according to standard treatment regulations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anastrozole</intervention_name>
    <description>Patients receive aromatase inhibitor therapy according to standard treatment regulations.</description>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exemestane</intervention_name>
    <description>Patients receive aromatase inhibitor therapy according to standard treatment regulations.</description>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fulvestrant</intervention_name>
    <description>Given intramuscularly</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
    <arm_group_label>Arm IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lapatinib ditosylate</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm III</arm_group_label>
    <arm_group_label>Arm IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>letrozole</intervention_name>
    <description>Patients receive aromatase inhibitor therapy according to standard treatment regulations.</description>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed breast cancer&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
          -  Confirmed disease progression after treatment with an aromatase inhibitor (AI)&#xD;
             administered in the adjuvant or metastatic setting&#xD;
&#xD;
               -  Must have demonstrated a prior response to AI therapy (i.e., responded after &gt; 2&#xD;
                  years of treatment in the adjuvant setting OR complete or partial response or&#xD;
                  stable disease after ≥ 24 weeks of treatment in the metastatic setting) AND have&#xD;
                  subsequent disease progression after completion of AI therapy&#xD;
&#xD;
          -  Meets 1 of the following criteria:&#xD;
&#xD;
               -  Measurable disease, defined as ≥ 1 lesion that can be accurately measured in ≥ 1&#xD;
                  dimension (longest diameter to be recorded) as ≥ 20 mm with conventional&#xD;
                  techniques or ≥ 10 mm with spiral CT scan&#xD;
&#xD;
               -  Evaluable disease, defined as bone lesions, lytic or mixed (lytic and sclerotic),&#xD;
                  evaluable by plain x-ray, CT scan, or MRI&#xD;
&#xD;
                    -  Lesions identified only by radionucleotide bone scan are not allowed&#xD;
&#xD;
          -  No HER2/neu-overexpressing tumor (IHC 3+ or FISH+)&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Estrogen receptor- and/or progesterone receptor-positive primary or metastatic&#xD;
                  tumor&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Postmenopausal, as defined by any of the following criteria:&#xD;
&#xD;
               -  At least 60 years of age&#xD;
&#xD;
               -  45 to 59 years of age and meets ≥ 1 of the following criteria:&#xD;
&#xD;
                    -  Amenorrhea for ≥ 12 months and intact uterus&#xD;
&#xD;
                    -  Amenorrhea for &lt; 12 months and follicle-stimulating hormone within the&#xD;
                       postmenopausal range (including patients with hysterectomy, prior hormone&#xD;
                       replacement therapy, or chemotherapy-induced amenorrhea)&#xD;
&#xD;
                         -  Patients who received prior luteinizing hormone-releasing hormone&#xD;
                            (LHRH) analogues must not have restarted their menses after cessation&#xD;
                            of therapy&#xD;
&#xD;
               -  Over 18 years of age and bilateral oophorectomy&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 8 months&#xD;
&#xD;
          -  Leukocytes ≥ 3,000/μL&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/μL&#xD;
&#xD;
          -  Platelet count ≥ 100,000/μL&#xD;
&#xD;
          -  Total bilirubin normal&#xD;
&#xD;
          -  AST/ALT ≤ 2.5 times upper limit of normal&#xD;
&#xD;
          -  Creatinine normal OR creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  LVEF normal as measured by ECHO or MUGA&#xD;
&#xD;
          -  Able to swallow and retain oral medication&#xD;
&#xD;
          -  No ulcerative colitis&#xD;
&#xD;
          -  No malabsorption syndrome or disease significantly affecting gastrointestinal function&#xD;
&#xD;
          -  No known history of uncontrolled or symptomatic angina, arrhythmias, or congestive&#xD;
             heart failure&#xD;
&#xD;
          -  No known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs&#xD;
             chemically related to fulvestrant, aromatase inhibitors, lapatinib tosylate, or&#xD;
             excipients&#xD;
&#xD;
          -  No unresolved or unstable serious toxicity from prior therapy&#xD;
&#xD;
          -  No active or uncontrolled infection&#xD;
&#xD;
          -  No dementia, altered mental status, or any psychiatric condition that would prohibit&#xD;
             the understanding or rendering of informed consent&#xD;
&#xD;
          -  No other malignancy within the past 5 years except for adequately treated cervical&#xD;
             carcinoma in situ, melanoma in situ, or basal cell or squamous cell carcinoma of the&#xD;
             skin&#xD;
&#xD;
          -  No other concurrent disease or condition that would make the patient inappropriate for&#xD;
             study participation&#xD;
&#xD;
          -  No serious medical disorder that would interfere with patient safety&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior radiotherapy for the primary or metastatic tumor allowed&#xD;
&#xD;
          -  More than 4 months since prior LHRH analogues&#xD;
&#xD;
          -  More than 30 days (or 5 half-lives, whichever is longer) since prior investigational&#xD;
             agents&#xD;
&#xD;
          -  More than 14 days since prior and no concurrent CYP3A4 inducers*, including any of the&#xD;
             following:&#xD;
&#xD;
               -  Rifampin, rifapentine, rifabutin, or other rifamycin class agents&#xD;
&#xD;
               -  Phenytoin, carbamazepine, or barbiturates (e.g., phenobarbital)&#xD;
&#xD;
               -  Efavirenz or nevirapine&#xD;
&#xD;
               -  Oral glucocorticoids (e.g., cortisone [&gt; 50 mg], hydrocortisone [&gt; 40 mg],&#xD;
                  prednisone [&gt; 10 mg], methylprednisolone [&gt; 8 mg], or dexamethasone [&gt; 1.5 mg])&#xD;
&#xD;
               -  Modafinil&#xD;
&#xD;
          -  More than 14 days since prior and no concurrent herbal or dietary supplements*,&#xD;
             including any of the following:&#xD;
&#xD;
               -  St. John's wort&#xD;
&#xD;
               -  Ginkgo biloba&#xD;
&#xD;
               -  Kava&#xD;
&#xD;
               -  Grape seed&#xD;
&#xD;
               -  Valerian&#xD;
&#xD;
               -  Ginseng&#xD;
&#xD;
               -  Echinacea&#xD;
&#xD;
               -  Evening primrose oil&#xD;
&#xD;
          -  More than 7 days since prior and no concurrent CYP3A4 inhibitors*, including any of&#xD;
             the following:&#xD;
&#xD;
               -  Clarithromycin, erythromycin, or troleandomycin&#xD;
&#xD;
               -  Itraconazole, ketoconazole, fluconazole (&gt; 150 mg daily), or voriconazole&#xD;
&#xD;
               -  Delaviridine, nelfinavir, amprenavir, ritonavir, indinavir, saquinavir, or&#xD;
                  lopinavir&#xD;
&#xD;
               -  Verapamil or diltiazem&#xD;
&#xD;
               -  Nefazodone or fluvoxamine&#xD;
&#xD;
               -  Cimetidine or aprepitant&#xD;
&#xD;
               -  Grapefruit or grapefruit juice&#xD;
&#xD;
          -  More than 6 months since prior and no concurrent amiodarone*&#xD;
&#xD;
          -  No prior fulvestrant and/or lapatinib tosylate&#xD;
&#xD;
          -  No prior resection of the stomach or small bowel&#xD;
&#xD;
          -  No other concurrent anticancer therapy, including chemotherapy, immunotherapy, and&#xD;
             biologic therapy&#xD;
&#xD;
               -  Concurrent bisphosphonates allowed&#xD;
&#xD;
          -  No other concurrent investigational therapy&#xD;
&#xD;
          -  No concurrent participation in another clinical trial NOTE: *For patients randomized&#xD;
             to receive lapatinib&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabino De Placido, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federico II University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Federico II University Medical School</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>39-081-746-3660</phone>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <study_first_submitted>May 30, 2008</study_first_submitted>
  <study_first_submitted_qc>May 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2008</study_first_posted>
  <last_update_submitted>August 23, 2013</last_update_submitted>
  <last_update_submitted_qc>August 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2013</last_update_posted>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Lapatinib</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Exemestane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

